Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fugan is a topical Traditional Chinese Medicine (TCM) ointment developed by Chengdu Baiter Pharmaceutical for the treatment of subacute eczema. It is specifically indicated for patients exhibiting the damp-heat pattern in TCM diagnosis. The formulation has undergone Phase II clinical testing in China (CTR20132041), where it was evaluated for efficacy and safety in adults with mild to moderate subacute eczema over a 21-day treatment period. Like many TCM preparations, it is a multi-ingredient botanical product designed to alleviate inflammation and itching associated with dermatological conditions by clearing heat and resolving dampness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fugan.